# PI3K/PIKK inhibitor payloads

Source: https://onco.cc/terms/pi3k-pikk-inhibitor-payloads/  
OnCo record `pi3k-pikk-inhibitor-payloads` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

These payloads block enzymes that support cancer-cell growth and stress responses. Antibody delivery is being studied as a way to direct those effects toward tumors.

## Summary

The primary AACR abstract for HMPL-A580 describes an EGFR-directed antibody carrying a PI3K/PIKK inhibitor through a cleavable linker. Cell and xenograft experiments reported intracellular delivery, pathway inhibition and antitumor activity. PI3K and PIKK denote different kinase families; this broad payload label must not be reduced to a single selective kinase target without supporting data. The cited evidence is a preclinical conference abstract, not a clinical efficacy report.

## Fields

- Kind: Term
- Last checked: 2026-11-08
- Also known as: HMPL-A580 payload; PI3K/PIKK antibody-targeted therapy conjugates

## Sources

- Cai et al., HMPL-A580 preclinical AACR abstract (2026): https://doi.org/10.1158/1538-7445.AM2026-4549

## Connected records

- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- terms: [Next-generation antibody-conjugate payloads](https://onco.cc/terms/next-generation-adc-payloads/), [Payload (ADC)](https://onco.cc/terms/payload/)

---
JSON: https://onco.cc/api/v1/entities/pi3k-pikk-inhibitor-payloads.json